乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义

doi:10.3969/j.issn.1004-616x.2021.03.013

癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (3): 230-235,245.doi: 10.3969/j.issn.1004-616x.2021.03.013

乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义

张玉铃¹, 吴俊东^2,3, 潘东岳², 陈春发^2,3

1. 汕头大学医学院附属肿瘤医院信息科, 广东汕头 515041;
2. 汕头大学医学院附属肿瘤医院乳腺中心, 广东汕头 515041;
3. 广东省乳腺癌诊治重点实验室, 广东汕头 515041

收稿日期:2020-11-28 修回日期:2021-03-09 出版日期:2021-05-30 发布日期:2021-06-09
通讯作者: 陈春发，E-mail：chenchunfa@stu.edu.cn E-mail:chenchunfa@stu.edu.cn
作者简介:张玉铃，E-mail：neroli1212@163.com。
基金资助:
汕头大学医学院附属肿瘤医院青年科研基金（2020A003）；广东省科技创新战略专项（汕府科2018-49）；广东省科技专项（汕府科2019-132）；汕头市科技计划（190816095262235；[2017]85）；广东省乳腺癌诊治研究重点实验室项目（2017B030314116）

Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers

ZHANG Yuling¹, WU Jundong^2,3, PANG Dongyue², CHEN Chunfa^2,3

1. Department of Medical Information, Cancer Hospital of Shantou University Medical College, Shantou 515041;
2. The Breast Cancer Center, Cancer Hospital of Shantou University Medical College, Shantou 515041;
3. Guangdong Provincial Key Laboratory for Breast Cancer Diagnosis, Shantou 515041, Guangdong, China

Received:2020-11-28 Revised:2021-03-09 Online:2021-05-30 Published:2021-06-09

摘要/Abstract

摘要： 目的：探讨乳腺癌新辅助化疗（NACT）前后Ki67表达变化对疗效和预后预测的临床意义。方法：回顾性分析汕头大学医学院附属肿瘤医院2009年12月—2013年9月期间收治的104例乳腺癌NACT后手术的患者。采用免疫组织化学评估配对的化疗前穿刺活检标本和手术切除标本中Ki67的表达情况。根据NACT前后Ki67的变化分为Ki67下降组和Ki67未下降（不变或升高）组，并对两组的临床病理学资料进行比较和生存分析。结果：NACT后Ki67下降组占62.5%（65/104），未下降组占37.5%（39/104）。NACT前高表达Ki67的患者经NACT后Ki67显著下降（63/91，P < 0.01）。Ki67下降组更容易获得有效的临床效果即达到临床完全/部分缓解（59/65，P=0.005），且NACT后Ki67下降值与临床疗效相关（r=0.302，P=0.002）。NACT后Ki67下降组的无病生存率明显高于Ki67未下降组，差异有统计学意义（P=0.027）；Ki67下降组的总生存率高于Ki67未下降组，但差异无统计学意义（P=0.171）。结论：乳腺癌NACT后Ki67表达下降可能是疗效和预后的预测因子。

关键词: Ki67, 乳腺肿瘤, 新辅助化疗, 疗效, 预后

Abstract: OBJECTIVE： To investigate changes of Ki67 expression before and after neoadjuvant chemotherapy (NACT) in breast cancer as a predictor of therapeutic response and prognosis. METHODS： Retrospective analyses were conducted on 104 patients with breast cancer who received NACT at the Shantou University Medical College Cancer Hospital from December 2009 to September 2013. Expression of Ki67 was assessed using immunohistochemistry in pre-chemotherapy core-needle biopsy and post-surgical specimens. Clinicopathological characteristics， therapeutic responses， and survival were compared between the Ki67- reduced group and the Ki67-unchanged/increased group during NAC. RESULTS： Both the reduced and unchanged/increased groups accounted for 62.5% (65/104) and 37.5% (39/104)，respectively. Ki67 levels were significantly reduced in patients with higher Ki67 expression (63/91， P < 0.01) before NACT. Patients with reduced Ki67 after NAC showed significantly enhanced therapeutic response，such as clinical complete response and clinical partial response (59/65， P=0.005). In addition， the decreased value of Ki67 during NACT was significantly correlated with therapeutic response (r=0.302， P=0.002). The disease- free survival rates in the Ki67 reduced group was higher than that in the Ki67 unchanged/increase group (P=0.027). The overall survival rates in the Ki67 reduced group was higher than that in the Ki67 unchanged/increase group，but the difference was not statistically significant (P=0.171). CONCLUSION： The reduction of Ki67 expression after NACT could be a predictor for therapeutic response and prognosis in breast cancers.

Key words: Ki67, breast neoplasms, neoadjuvant chemotherapy, therapeutic response, prognosis

中图分类号:

R737.9

张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.

ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.

参考文献

[1] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018, 19(1): 27-39.
[2] MARTELLI G, MICELI R, FOLLI S, et al. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study[J]. Eur J Surg Oncol, 2017, 43(11): 2012-2020.
[3] BOUGHEY J C, SUMAN V J, MITTENDORF E A, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071(Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
[4] 陈灿铭, 沈镇宙. 乳腺癌新辅助化疗疗效预测因子的研究现状[J]. 循证医学, 2007, 7(3): 132-134.
[5] TAN P H, BAY B H, YIP G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death[J]. Mod Pathol, 2005, 18(3): 374-381.
[6] VINCENT-SALOMON A, ROUSSEAU A, JOUVE M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy[J]. Eur J Cancer, 2004, 40(10): 1502-1508.
[7] VON MINCKWITZ G, SCHMITT W D, LOIBL S, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer[J]. Clin Cancer Res, 2013, 19(16): 4521-4531.
[8] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
[9] CHEN C F, ZHANG Y L, HUANG Z Y, et al. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer[J]. Cancer Biol Med, 2019, 16(3): 575-586.
[10] DOWSETT M, NIELSEN T O, A'HERN R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group[J]. J Natl Cancer Inst, 2011, 103(22): 1656-1664.
[11] CHEANG M C, CHIA S K, VODUC D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101(10): 736-750.
[12] YERUSHALMI R, WOODS R, RAVDIN P M, et al. Ki67 in breast cancer: prognostic and predictive potential[J]. Lancet Oncol, 2010, 11(2): 174-183.
[13] GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
[14] JONES R L, SALTER J, A'HERN R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer[J]. Breast Cancer Res Treat, 2010, 119(2): 315-323.
[15] TAN Q X, QIN Q H, YANG W P, et al. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy[J]. Int J Clin Exp Pathol, 2014, 7(10): 6862-6870.
[16] URRUTICOECHEA A, SMITH I E, DOWSETT M. Proliferation marker Ki-67 in early breast cancer[J]. J Clin Oncol, 2005, 23(28): 7212-7220.
[17] FASCHING P A, HEUSINGER K, HAEBERLE L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J]. BMC Cancer, 2011, 11: 486.
[18] ELLIS M J, TAO Y, LUO J Q, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics[J]. J Natl Cancer Inst, 2008, 100(19): 1380-1388.
[19] JONES R L, SALTER J, A’HERN R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2009, 116(1): 53-68.
[20] ASSERSOHN L, SALTER J, POWLES T J, et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer[J]. Breast Cancer Res Treat, 2003, 82(2): 113-123.
[21] SUETA A, YAMAMOTO Y, HAYASHI M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?[J]. Surgery, 2014, 155(5): 927-935.
[22] KIM K I, LEE K H, KIM T R, et al. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients [J]. J Breast Cancer, 2014, 17(1): 40-46.
[23] CHEN R, YE Y, YANG C C, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients [J]. Breast Cancer Res Treat, 2018, 170(1): 35-43.
[24] 余海云, 李文萍, 郜红艺, 等. 新辅助化疗疗效与乳腺癌Ki67、 P53表达的关系[J]. 中华乳腺病杂志: 电子版, 2011, 5(3): 297-305.
[25] DENKERT C, BUDCZIES J, VON MINCKWITZ G, et al. Strategies for developing Ki67 as a useful biomarker in breast cancer[J]. Breast, 2015, 24(Sup 2): S67-S72.
[26] PAIK S, SHAK S, TANG G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J]. N Engl J Med, 2004, 351(27): 2817-2826.
[27] SHERI A, SMITH I E, JOHNSTON S R, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy[J]. Ann Oncol, 2015, 26(1): 75-80.
[28] YOSHIOKA T, HOSODA M, YAMAMOTO M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer, 2015, 22(2): 185-191.

乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义

Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[5]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[6]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[7]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[8]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[9]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[10]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[11]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[12]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[13]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.
[14]	吕燕萍, 吴传城, 杨双凤, 何陈周, 韩仁杰, 颜伟, 刘宝英. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变·畸变·突变, 2020, 32(5): 380-386.
[15]	郭秀娟, 杜彦艳, 颜晰, 赵学涛, 韩丽娜, 武一鹏, 王雪晓, 马鸣. CREB在食管鳞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 387-390,394.